GlobalRPh RX List - NOCTIVA
- Product / population
- Desmopressin - NOCTIVA nasal spray; selected source sections, not a full prescribing monograph.
- Renal measure
- eGFR, mL/min/1.73 m2; retain body-surface-area indexing.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
This nasal product is contraindicated below eGFR 50 mL/min/1.73 m2. The renal study showed approximately three- to four-fold higher exposure and half-life below that threshold. Additional exclusions include hyponatremia history, loop diuretics, systemic or inhaled glucocorticoids, uncontrolled hypertension and NYHA II-IV heart failure. This is selected restriction evidence, not a current-market availability determination or a complete nocturia prescribing protocol. Do not substitute the sublingual product dose for this nasal formulation.